Navigation Links
Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
Date:2/20/2008

are of loss recorded in the current year has reduced the Company's long-term investment in Innodia Holding to a nominal value. Innodia Inc. is a private, development-stage company engaged in developing novel drugs for the treatment of Type II diabetes and underlying diseases.

Liquidity and capital resources

As at December 31, 2007, the Company had available cash, cash equivalents and marketable securities of $58,672,000, compared to $48,758,000 at December 31, 2006. The increase is primarily due to proceeds received from the issue of convertible notes in May 2007 and is partially offset by funds used in operating activities.

On May 2, 2007, the Company issued $80,000,000 aggregate principal amount of convertible notes, consisting of $40,000,000 6% senior convertible notes due in 2027 and $40,000,000 5% senior subordinated convertible notes due in 2012. The 6% senior convertible notes have an initial conversion price equal to the lesser of $12.68 or the 5-day weighted average trading price of the common shares preceding any conversion, subject to adjustments in certain circumstances. The Company will pay interest on the 6% senior convertible notes until maturity on May 2, 2027, subject to earlier repurchase, redemption or conversion. The 5% senior subordinated convertible notes were subject to mandatory conversion into common shares under certain circumstances. In connection with this transaction, the Company issued warrants to purchase an aggregate of 2,250,645 common shares until May 2, 2012, at an initial purchase price of $12.68 per share, subject to adjustments in certain circumstances. . During the year ended December 31, 2007, $35,500,000 of the 6% senior convertible notes were converted into 5,619,321 common shares and the totality of the 5% senior subordinated convertible notes were converted into 4,444,449 common shares. Net proceeds from the offering were $74,279,000 and, as of December 31, 2007, $34,274,000 has yet to be spent. As at
'/>"/>

SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine news :

1. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
2. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
3. Neurochem to present at JPMorgan Healthcare Conference
4. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
5. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
6. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
7. Neurochem reports results for third quarter of fiscal 2007
8. Emageon Reports Fourth Quarter and 2007 Financial Results
9. Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
10. Platinum Underwriters Holdings, Ltd. Reports Record Fourth Quarter and Year Ended December 31, 2007 Financial Results
11. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... reveals that unplanned births out-of-hospital in Norway are associated ... Acta Obstetricia et Gynecologica Scandinavica , a journal of ... indicate that young women who have given birth at ... areas are more likely to have unplanned deliveries, which ... , In 2013, close to 60,000 babies were born ...
(Date:9/2/2014)... (PRWEB) September 03, 2014 Everyone of a ... offers two easy ways to help minimize them and improve ... ingredients. Aging skin needs to boost collagen levels, which diminish ... sagging skin. Skin also needs to be well hydrated, as ... from the sun and good diet that nourishes skin, two ...
(Date:9/2/2014)... Chicago, Illinois (PRWEB) September 02, 2014 ... Hospital Chief Executive Officer and Chief Information Officer ... Ritz Carlton Chicago. , Becker's Hospital Review Chief ... bring together hospital and health system Chief Executive ... other hospital and health system executives through ...
(Date:9/2/2014)... iFitDress.com, a famous online supplier of wedding dresses and ... 2014 seashell wedding dresses . Additionally, these elegant ... proportion of them are priced under $190. , All ... by the most skilled workers. Along with seashell wedding ... wedding gowns, white halter wedding gowns, regency evening outfits, ...
(Date:9/2/2014)... The exciting information sessions and AMTC auditions will ... and Bob Wiley. The team of scouts prayerfully ... desire to illuminate entertainment with the light of Christ. ... to join the Bridge Training Program and ... 6, Charlotte Convention Center, 501 South College St., Charlotte, ...
Breaking Medicine News(10 mins):Health News:Unplanned births out-of-hospital increases risk of infant mortality 2Health News:2 Natural Ways to Relax and Reduce Wrinkles From Sublime Beauty® 2Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 2Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 3Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 4Health News:Discounted Seashell Wedding Dresses Currently Provided By iFitDress.com 2Health News:Actors, Models and Talent for Christ Auditions Are Set for Charlotte and Omaha on Saturday, September 6, 2014 2
... (Nasdaq: MEMY ) today announced the issuance ... matter patent,protection for a series of nicotinic alpha-7 ... which are both being developed,in partnership with Roche ... disease and cognitive impairment associated with schizophrenia,(CIAS). The ...
... Baby boomers are turning 62,every seven seconds. ... their,own health care in their senior years, says ... Care insurance lawyer., (Photo: http://www.newscom.com/cgi-bin/prnh/20070717/NYFNSC02 ), ... Care. It has been sold and,marketed to our ...
... ConvergeWireless Inc., of Ontario Canada, a Value Added Wireless Application ... been certified by the AT&T Developer Program. MyMileageGenie & MyFormsGenie ... for Enterprise Sales. , ... Ontario, ...
... DETROIT, Oct. 24 For the second ... has been chosen as the most,preferred hospital ... to the,2008 Cancer Treatment Preference Profile Survey ... http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSCANCERINSTITUTELOGO ), The annual survey, ...
... body, checking arteries lowers risk of further injury , , THURSDAY, ... is only the first step in saving a life after ... advisory, published in the Oct. 23 issue of Circulation ... resuscitation or risk the losing the patient to the original ...
... Alternext US: FIT), a leading provider of integrated,employee ... report financial results for the third quarter ended ... the market closes. The company will also,hold a ... results. Participating,in the call will be Dr. Gregg ...
Cached Medicine News:Health News:Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908 2Health News:Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908 3Health News:Expert Says Conseco Trust May Significantly Alter The Senior Health Care Market 2Health News:MyMileageGenie & MyFormsGenie Certified by the AT&T Developer Program 2Health News:MyMileageGenie & MyFormsGenie Certified by the AT&T Developer Program 3Health News:MyMileageGenie & MyFormsGenie Certified by the AT&T Developer Program 4Health News:Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan 2Health News:Speedy Care After Heart Attack Key to Survival 2Health News:HealthFitness Corporation to Report 2008 Third Quarter Financial Results 2
(Date:9/2/2014)... 2014  Ameritox SM , the nation,s leader in ... Drugs to Heroin," a research report that provides concrete ... examines deadly trends that have created a unique heroin ... The report is based on data ... It examines five trends that distinguish the heroin abuse ...
(Date:9/2/2014)... BARCELONA , Spanien, September 2, ... -- Das auf dem ESC-Kongress 2014 ... die Behandlung und Behandlungsergebnisse von schlaganfallgefährdeten ...    Die Daten ... eingetragenen Patienten, einer innovativen und unabhängigen ...
(Date:9/2/2014)... Spain , September 2, 2014 ... decisions, including patients, quality of life and treatment satisfaction ... 2 ]   ... ESC Congress 2014, 02 September 2014, Barcelona, ... results of the PREvention oF thromboembolic events-European Registry in ...
Breaking Medicine Technology:Ameritox Research Report Reveals Pain Patients' Role in Current Heroin Epidemic 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 2One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 3One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 4One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 5One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 6One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 7One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 8
... (Nasdaq: IDIX ), a biopharmaceutical company engaged ... treatment of human viral diseases, today reported unaudited financial ... September 30, 2010. At September 30, 2010, Idenix,s cash ... Third Quarter 2010 Financial ResultsFor the third quarter ended ...
... ViroPharma Incorporated (Nasdaq: VPHM ) today ... ViroPharma, will present at the Oppenheimer 21st Annual Healthcare ... 2010.  The conference is being held at the Waldorf=Astoria ... president and chief financial officer, of ViroPharma, will present ...
Cached Medicine Technology:Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results 2Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results 3Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results 4Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results 5ViroPharma to Participate in Several Upcoming Healthcare Investor Conferences 2
... Basic ergonomic chairs with ... with lumbar support • Select ... and casters and glides. • ... the following environments: industry, education, ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTT/1P chairs are recommended for ... clean room, static control, health care ...
... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
Medicine Products: